Scholarlink

Background <p>The prevalence of (pre)obesity and its consequences are exploding worldwide. Anti-obesity medication (AOM) has a&#xa0;firm place in international guidelines. In Asia complementary additive medicine (CAM) also plays a&#xa0;role in multimodal treatment concepts.</p> Objective <p>The influence of AOM on patient acceptance of Traditional Chinese Medicine (TCM) for the treatment of (pre)obesity and its comorbidities.</p> Material and methods <p>In this retrospective cross-sectional study 479 (pre)obese patients at the Inselspital Bern, Switzerland completed the anonymous bariatric basic questionnaire for Traditional Chinese Medicine (BARBQTCM) between 2017 and 2018.</p> Results <p>Of the cohort two thirds were female, obese (body mass index, BMI: 35 kg/m<sup>2</sup>) and 42&#xa0;years old. Of the respondents two fifths had experience with CAM (39.7%) and AOM (40.7%) and four fifths were interested in TCM treatment (81.2%). The AOM cohort had more CAM experience (51.3% vs. 31.7%; <i>p</i> &lt; 0.001) and would use TCM treatment (85.1% vs. 77.5%; <i>p</i> = 0.07) more frequently than the control group. Furthermore, the AOM group would visit a&#xa0;TCM outpatient clinic more frequently (1–2 ×/month: 51.3% vs. 43.7%) and spend more money on TCM (51–100 Swiss francs/month: 33.8% vs. 21.1%; <i>p</i> = 0.002) than the comparison group. Significant factors influencing increased TCM acceptance were experience with CAM (odds ratio, OR: 4.49; <i>p</i> &lt; 0.001) and female gender (OR: 1.88; <i>p = 0.009</i>). Experience with AOM (OR: 1.57; <i>p</i> = 0.075) showed a trend, but age &gt; 40&#xa0;years and BMI ≤ 35 had no influence on TCM acceptance.</p> Discussion <p>Conventional pharmacological and invasive treatment for (pre)obesity occasionally has side effects and contraindications. Given the high patient preference, TCM can be integrated into evidence-based multimodal guidelines, even in Europe.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Einfluss von Appetitzüglern auf die TCM-Akzeptanz bei (Prä‑)Adipösen

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月19日

查看全文
  • Anna Happe,
  • Steffi Rothe,
  • Thomas Vlasak,
  • Dino Kröll,
  • Philipp Nett,
  • Peter Panhofer

摘要

Background

The prevalence of (pre)obesity and its consequences are exploding worldwide. Anti-obesity medication (AOM) has a firm place in international guidelines. In Asia complementary additive medicine (CAM) also plays a role in multimodal treatment concepts.

Objective

The influence of AOM on patient acceptance of Traditional Chinese Medicine (TCM) for the treatment of (pre)obesity and its comorbidities.

Material and methods

In this retrospective cross-sectional study 479 (pre)obese patients at the Inselspital Bern, Switzerland completed the anonymous bariatric basic questionnaire for Traditional Chinese Medicine (BARBQTCM) between 2017 and 2018.

Results

Of the cohort two thirds were female, obese (body mass index, BMI: 35 kg/m2) and 42 years old. Of the respondents two fifths had experience with CAM (39.7%) and AOM (40.7%) and four fifths were interested in TCM treatment (81.2%). The AOM cohort had more CAM experience (51.3% vs. 31.7%; p < 0.001) and would use TCM treatment (85.1% vs. 77.5%; p = 0.07) more frequently than the control group. Furthermore, the AOM group would visit a TCM outpatient clinic more frequently (1–2 ×/month: 51.3% vs. 43.7%) and spend more money on TCM (51–100 Swiss francs/month: 33.8% vs. 21.1%; p = 0.002) than the comparison group. Significant factors influencing increased TCM acceptance were experience with CAM (odds ratio, OR: 4.49; p < 0.001) and female gender (OR: 1.88; p = 0.009). Experience with AOM (OR: 1.57; p = 0.075) showed a trend, but age > 40 years and BMI ≤ 35 had no influence on TCM acceptance.

Discussion

Conventional pharmacological and invasive treatment for (pre)obesity occasionally has side effects and contraindications. Given the high patient preference, TCM can be integrated into evidence-based multimodal guidelines, even in Europe.